Global Hereditary Angioedema Therapeutics Market 2023-2027

Description

List of Tables

The hereditary angioedema therapeutics market is forecasted to grow by USD 1647.38 mn during 2022-2027, accelerating at a CAGR of 8.95% during the forecast period. The report on the hereditary angioedema therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of hereditary angioedema, advancements in diagnostic techniques, and growing healthcare infrastructure.

Technavio's hereditary angioedema therapeutics market is segmented as below:

By End-user

Hospital pharmacies
Retail pharmacies
E-commerce

By Product

C1-esterase inhibitor
Bradykinin B2 receptor antagonist
Kallikrein inhibitor
Others

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the growing demand for personalized medicine as one of the prime reasons driving the hereditary angioedema therapeutics market growth during the next few years. Also, development of innovative and effective therapeutics, such as monoclonal antibodies and gene therapy and increasing R and D and funding for orphan drug development will lead to sizable demand in the market.

The report on the hereditary angioedema therapeutics market covers the following areas:

Hereditary angioedema therapeutics market sizing
Hereditary angioedema therapeutics market forecast
Hereditary angioedema therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hereditary angioedema therapeutics market vendors that include Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., CENTOGENE NV, Cipla Ltd., CSL Ltd., Diapharma Group Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Pharming Group NV, Pharvaris NV, Sanofi, and Takeda Pharmaceutical Co. Ltd.. Also, the hereditary angioedema therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR75935

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by End-user
Exhibit 06: Executive Summary - Chart on Market Segmentation by Product
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global hereditary angioedema therapeutics market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on global hereditary angioedema therapeutics market 2017 - 2021 ($ million)
4.2 End-User Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - End-User Segment 2017 - 2021 ($ million)
4.3 Product Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Product Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by End-user

6.1 Market segments
Exhibit 30: Chart on End-user - Market share 2022-2027 (%)
Exhibit 31: Data Table on End-user - Market share 2022-2027 (%)
6.2 Comparison by End-user
Exhibit 32: Chart on Comparison by End-user
Exhibit 33: Data Table on Comparison by End-user
6.3 Hospital pharmacies - Market size and forecast 2022-2027
Exhibit 34: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
6.4 Retail pharmacies - Market size and forecast 2022-2027
Exhibit 38: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
6.5 E-commerce - Market size and forecast 2022-2027
Exhibit 42: Chart on E-commerce - Market size and forecast 2022-2027 ($ million)
Exhibit 43: Data Table on E-commerce - Market size and forecast 2022-2027 ($ million)
Exhibit 44: Chart on E-commerce - Year-over-year growth 2022-2027 (%)
Exhibit 45: Data Table on E-commerce - Year-over-year growth 2022-2027 (%)
6.6 Market opportunity by End-user
Exhibit 46: Market opportunity by End-user ($ million)
Exhibit 47: Data Table on Market opportunity by End-user ($ million)

7 Market Segmentation by Product

7.1 Market segments
Exhibit 48: Chart on Product - Market share 2022-2027 (%)
Exhibit 49: Data Table on Product - Market share 2022-2027 (%)
7.2 Comparison by Product
Exhibit 50: Chart on Comparison by Product
Exhibit 51: Data Table on Comparison by Product
7.3 C1-esterase inhibitor - Market size and forecast 2022-2027
Exhibit 52: Chart on C1-esterase inhibitor - Market size and forecast 2022-2027 ($ million)
Exhibit 53: Data Table on C1-esterase inhibitor - Market size and forecast 2022-2027 ($ million)
Exhibit 54: Chart on C1-esterase inhibitor - Year-over-year growth 2022-2027 (%)
Exhibit 55: Data Table on C1-esterase inhibitor - Year-over-year growth 2022-2027 (%)
7.4 Bradykinin B2 receptor antagonist - Market size and forecast 2022-2027
Exhibit 56: Chart on Bradykinin B2 receptor antagonist - Market size and forecast 2022-2027 ($ million)
Exhibit 57: Data Table on Bradykinin B2 receptor antagonist - Market size and forecast 2022-2027 ($ million)
Exhibit 58: Chart on Bradykinin B2 receptor antagonist - Year-over-year growth 2022-2027 (%)
Exhibit 59: Data Table on Bradykinin B2 receptor antagonist - Year-over-year growth 2022-2027 (%)
7.5 Kallikrein inhibitor - Market size and forecast 2022-2027
Exhibit 60: Chart on Kallikrein inhibitor - Market size and forecast 2022-2027 ($ million)
Exhibit 61: Data Table on Kallikrein inhibitor - Market size and forecast 2022-2027 ($ million)
Exhibit 62: Chart on Kallikrein inhibitor - Year-over-year growth 2022-2027 (%)
Exhibit 63: Data Table on Kallikrein inhibitor - Year-over-year growth 2022-2027 (%)
7.6 Others - Market size and forecast 2022-2027
Exhibit 64: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 65: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 66: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibit 67: Data Table on Others - Year-over-year growth 2022-2027 (%)
7.7 Market opportunity by Product
Exhibit 68: Market opportunity by Product ($ million)
Exhibit 69: Data Table on Market opportunity by Product ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 71: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibit 72: Data Table on Market share By Geographical Landscape 2022-2027 (%)
9.2 Geographic comparison
Exhibit 73: Chart on Geographic comparison
Exhibit 74: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 83: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 84: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 85: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 86: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 China - Market size and forecast 2022-2027
Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)
9.9 Germany - Market size and forecast 2022-2027
Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.10 Canada - Market size and forecast 2022-2027
Exhibit 103: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 104: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 105: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibit 106: Data Table on Canada - Year-over-year growth 2022-2027 (%)
9.11 India - Market size and forecast 2022-2027
Exhibit 107: Chart on India - Market size and forecast 2022-2027 ($ million)
Exhibit 108: Data Table on India - Market size and forecast 2022-2027 ($ million)
Exhibit 109: Chart on India - Year-over-year growth 2022-2027 (%)
Exhibit 110: Data Table on India - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 111: Market opportunity By Geographical Landscape ($ million)
Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 113: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 115: Overview on factors of disruption
11.4 Industry risks
Exhibit 116: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 117: Vendors covered
12.2 Market positioning of vendors
Exhibit 118: Matrix on vendor position and classification
12.3 Adverum Biotechnologies Inc.
Exhibit 119: Adverum Biotechnologies Inc. - Overview
Exhibit 120: Adverum Biotechnologies Inc. - Product / Service
Exhibit 121: Adverum Biotechnologies Inc. - Key offerings
12.4 Arrowhead Pharmaceuticals Inc.
Exhibit 122: Arrowhead Pharmaceuticals Inc. - Overview
Exhibit 123: Arrowhead Pharmaceuticals Inc. - Business segments
Exhibit 124: Arrowhead Pharmaceuticals Inc. - Key offerings
Exhibit 125: Arrowhead Pharmaceuticals Inc. - Segment focus
12.5 Attune Pharmaceuticals Inc.
Exhibit 126: Attune Pharmaceuticals Inc. - Overview
Exhibit 127: Attune Pharmaceuticals Inc. - Product / Service
Exhibit 128: Attune Pharmaceuticals Inc. - Key offerings
12.6 BioCryst Pharmaceuticals Inc.
Exhibit 129: BioCryst Pharmaceuticals Inc. - Overview
Exhibit 130: BioCryst Pharmaceuticals Inc. - Product / Service
Exhibit 131: BioCryst Pharmaceuticals Inc. - Key offerings
12.7 BioMarin Pharmaceutical Inc.
Exhibit 132: BioMarin Pharmaceutical Inc. - Overview
Exhibit 133: BioMarin Pharmaceutical Inc. - Product / Service
Exhibit 134: BioMarin Pharmaceutical Inc. - Key offerings
12.8 CENTOGENE NV
Exhibit 135: CENTOGENE NV - Overview
Exhibit 136: CENTOGENE NV - Product / Service
Exhibit 137: CENTOGENE NV - Key offerings
12.9 Cipla Ltd.
Exhibit 138: Cipla Ltd. - Overview
Exhibit 139: Cipla Ltd. - Business segments
Exhibit 140: Cipla Ltd. - Key news
Exhibit 141: Cipla Ltd. - Key offerings
Exhibit 142: Cipla Ltd. - Segment focus
12.10 CSL Ltd.
Exhibit 143: CSL Ltd. - Overview
Exhibit 144: CSL Ltd. - Business segments
Exhibit 145: CSL Ltd. - Key news
Exhibit 146: CSL Ltd. - Key offerings
Exhibit 147: CSL Ltd. - Segment focus
12.11 Intellia Therapeutics Inc.
Exhibit 148: Intellia Therapeutics Inc. - Overview
Exhibit 149: Intellia Therapeutics Inc. - Business segments
Exhibit 150: Intellia Therapeutics Inc. - Key offerings
Exhibit 151: Intellia Therapeutics Inc. - Segment focus
12.12 Ionis Pharmaceuticals Inc.
Exhibit 152: Ionis Pharmaceuticals Inc. - Overview
Exhibit 153: Ionis Pharmaceuticals Inc. - Business segments
Exhibit 154: Ionis Pharmaceuticals Inc. - Key news
Exhibit 155: Ionis Pharmaceuticals Inc. - Key offerings
Exhibit 156: Ionis Pharmaceuticals Inc. - Segment focus
12.13 KalVista Pharmaceuticals Inc.
Exhibit 157: KalVista Pharmaceuticals Inc. - Overview
Exhibit 158: KalVista Pharmaceuticals Inc. - Product / Service
Exhibit 159: KalVista Pharmaceuticals Inc. - Key offerings
12.14 Pharming Group NV
Exhibit 160: Pharming Group NV - Overview
Exhibit 161: Pharming Group NV - Business segments
Exhibit 162: Pharming Group NV - Key offerings
Exhibit 163: Pharming Group NV - Segment focus
12.15 Pharvaris NV
Exhibit 164: Pharvaris NV - Overview
Exhibit 165: Pharvaris NV - Product / Service
Exhibit 166: Pharvaris NV - Key offerings
12.16 Sanofi
Exhibit 167: Sanofi - Overview
Exhibit 168: Sanofi - Business segments
Exhibit 169: Sanofi - Key news
Exhibit 170: Sanofi - Key offerings
Exhibit 171: Sanofi - Segment focus
12.17 Takeda Pharmaceutical Co. Ltd.
Exhibit 172: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibit 173: Takeda Pharmaceutical Co. Ltd. - Product / Service
Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibit 175: Takeda Pharmaceutical Co. Ltd. - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 176: Inclusions checklist
Exhibit 177: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 178: Currency conversion rates for US$
13.4 Research methodology
Exhibit 179: Research methodology
Exhibit 180: Validation techniques employed for market sizing
Exhibit 181: Information sources
13.5 List of abbreviations
Exhibit 182: List of abbreviations